Ruolan Wang

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk, Faïza Ajana, Fiona Bisshop et al. · Clinical Infectious Diseases · 2020 · 257 citations · Full text

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

Kendra E. Hightower, Ruolan Wang, Felix Deanda et al. · Antimicrobial Agents and Chemotherapy · 2011 · 221 citations

Immunology, Molecular Biology, Slower Dissociation +18

Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-β Type I Receptor Inhibitors

Françoise Gellibert, James M. Woolven, Marie-Hélène Fouchet et al. · Journal of Medicinal Chemistry · 2004 · 217 citations · Full text

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana et al. · Clinical Infectious Diseases · 2022 · 123 citations · Full text

Developing digital fluency through ubiquitous mobile devices: Findings from a small-scale study

Ruolan Wang, Rolf Wiesemes, Cathy Gibbons · Computers & Education · 2011 · 99 citations

Digital Literacy, Engineering, Small-scale Study +9